Clinical Trial Update: Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating ixazomib citrate in patients with relapsed multiple myeloma that is not refractory to bortezomib has completed and posted results on …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Ninlaro (ixazomib citrate) (ixazomib)

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2024-06-13